THE PURE-PLAY DERMATOLOGY CATEGORY LEADER
Galderma is the leading company solely dedicated to the human body’s largest organ: the skin. We are recognized for our innovative, science-based portfolio of premium flagship brands and services that spans the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology.
Our unique Integrated Dermatology Strategy is the driving force behind our growth. It is our differentiating factor, and underscores our ambition to become the world’s undisputed dermatology powerhouse.
We work in close partnership with healthcare professionals to earn their trust and to meet individual consumer and patient needs, with superior outcomes.
As a trusted partner for healthcare professionals across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology, we are committed to being at the forefront of medical education and training in this field. We strive to maintain the highest education standards, ensuring the best treatment and advice for the people we serve.
KEY FACTS ABOUT GALDERMA
5.207 B USD
2025 net sales
4
manufacturing sites
410
million units produced a year
7,600+
employees worldwide
170+
clinical trials conducted in 2025
300
major regulatory approvals since 2020
10,000+
medical aesthetics education and training events hosted via the Global Aesthetic Injector Network (GAIN) program in 2025
290,000+
healthcare professionals reached through education, training and medical awareness activities
Our path towards becoming the undisputed dermatology powerhouse
A timeline of our history
1981
Foundation of Galderma as a joint venture between L’Oréal and Nestlé
Following the invention of the first Cetaphil formulation in 1947
1984
Galderma discovers Adapalene
1986
First commercial operations
1995
Launch of Differin for acne treatment
2000
Opening of our production site in Baie d’Urfé, Canada
2001
Licensing agreement for Metvix (Skin cancer)
2004
Opening of our production site in Hortolândia, Brazil
2007
Launch of Differin 0.3%
2008
Launch of Epiduo
2009
Launch of Azzalure and Restylane Injector
